Absci Corp (ABSI)
4.21
-0.04
(-0.94%)
USD |
NASDAQ |
May 31, 16:00
4.19
-0.02
(-0.48%)
After-Hours: 20:00
Absci Enterprise Value: 321.59M for May 31, 2024
Enterprise Value Chart
Historical Enterprise Value Data
Date | Value |
---|---|
May 31, 2024 | 321.59M |
May 30, 2024 | 326.11M |
May 29, 2024 | 318.19M |
May 28, 2024 | 328.37M |
May 24, 2024 | 321.59M |
May 23, 2024 | 337.42M |
May 22, 2024 | 366.82M |
May 21, 2024 | 387.17M |
May 20, 2024 | 366.82M |
May 17, 2024 | 367.38M |
May 16, 2024 | 381.52M |
May 15, 2024 | 391.13M |
May 14, 2024 | 391.70M |
May 13, 2024 | 417.71M |
May 10, 2024 | 400.74M |
May 09, 2024 | 426.75M |
May 08, 2024 | 404.14M |
May 07, 2024 | 410.92M |
May 06, 2024 | 434.67M |
May 03, 2024 | 419.97M |
May 02, 2024 | 408.66M |
May 01, 2024 | 432.41M |
April 30, 2024 | 381.52M |
April 29, 2024 | 386.04M |
April 26, 2024 | 363.42M |
Date | Value |
---|---|
April 25, 2024 | 349.29M |
April 24, 2024 | 357.77M |
April 23, 2024 | 378.13M |
April 22, 2024 | 355.51M |
April 19, 2024 | 384.91M |
April 18, 2024 | 407.53M |
April 17, 2024 | 443.71M |
April 16, 2024 | 453.89M |
April 15, 2024 | 459.55M |
April 12, 2024 | 504.29M |
April 11, 2024 | 533.10M |
April 10, 2024 | 532.54M |
April 09, 2024 | 589.60M |
April 08, 2024 | 482.82M |
April 05, 2024 | 494.12M |
April 04, 2024 | 477.17M |
April 03, 2024 | 445.53M |
April 02, 2024 | 426.32M |
April 01, 2024 | 479.43M |
March 31, 2024 | 487.34M |
March 28, 2024 | 550.88M |
March 27, 2024 | 535.09M |
March 26, 2024 | 497.87M |
March 25, 2024 | 480.95M |
March 22, 2024 | 468.54M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
-25.76M
Minimum
May 16 2023
3.011B
Maximum
Aug 03 2021
362.22M
Average
135.83M
Median
Enterprise Value Benchmarks
Eli Lilly and Co | 803.37B |
Creative Medical Technology Holdings Inc | -3.035M |
CytomX Therapeutics Inc | -17.82M |
Bristol-Myers Squibb Co | 129.36B |
Recursion Pharmaceuticals Inc | 1.668B |
Enterprise Value Related Metrics
Net Income (Quarterly) | -21.98M |
Revenue (Quarterly) | 0.898M |
Total Expenses (Quarterly) | 24.40M |
EPS Diluted (Quarterly) | -0.22 |
Profit Margin (Quarterly) | -2.45K% |
Earnings Yield | -27.55% |
Normalized Earnings Yield | -23.19 |